Phase 1 Macular Degeneration Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People of any sex who are 18 years of age or older.
• People who speak English and are able to understand and sign a consent form.
• People who are willing to follow all study procedures and are available for the full duration of the study.
• People who are in generally good health and have a confirmed diagnosis of inherited retinal dystrophy or dry age-related macular degeneration (dry-AMD).
• People whose best corrected vision in their better eye falls somewhere between 20/20 (with certain visual field limitations) and being able to detect only light.
• People whose eye scan (a specific type of retinal imaging called SD-OCT) shows that certain inner layers of the retina are still intact.
• People who are able to take medication by mouth and are willing to follow the required medication schedule.
• People who have been diagnosed with alcohol use disorder by an addiction specialist and have been identified as a candidate for treatment with disulfiram for that condition.
• People who agree to avoid all alcohol consumption for 180 days.
• Women of childbearing potential must have a negative pregnancy test at their screening visit.
• Women of childbearing potential must either have had a surgical sterilisation procedure (such as a vasectomy by their partner, hysterectomy, or tubal ligation), be completely abstinent from sexual intercourse, or agree to use two approved forms of contraception throughout the study and for at least one week after finishing the study medication. Approved methods include hormonal contraception (such as pills, injections, patches, or vaginal rings), intrauterine devices, or barrier methods (such as diaphragms or condoms) used with spermicide.

Who may not be able to join:

• People with a medical condition that the trial investigator believes would make participation unsafe, such as cardiovascular disease or hepatitis.
• People with a history of diabetes.
• People with a history of psychosis.
• People who have hypothyroidism (an underactive thyroid).
• People who have had an allergic skin reaction to thiuram derivatives, such as rubber contact dermatitis.
• People who are currently taking blood-thinning medication or other medications that may interact with the study drug, disulfiram.
• People who have other eye conditions that independently affect vision, such as diabetic retinopathy, glaucoma, cataracts, bleeding in the eye, retinal detachment, active eye inflammation, active eye infections, or abnormal blood vessel growth under the retina.
• People who have no light perception at all in both eyes.
• People who have had major eye surgery within the 6 months before joining, or who are expected to need major eye surgery within 6 months after joining the study.
• People who show signs of a significant external eye infection at examination, such as conjunctivitis, a chalazion (an eyelid cyst), or significant eyelid inflammation.
• People who have taken part in another clinical trial involving an unapproved drug within 30 days of joining, or who would need to take another experimental drug during this study.
• People with a known allergy or sensitivity to any ingredient in the study drug.
• Women who are pregnant, breastfeeding, or planning to become pregnant within the next 12 months.
• People who expect to move away from the area of the trial centre during the 8-month study period.

Important: Always verify eligibility with the trial site directly before applying.